Japan· JP-3999474G1023
ウステキヌマブ（遺伝子組換え）［ウステキヌマブ後続２］
A medicinal product containing ウステキヌマブ（遺伝子組換え）［ウステキヌマブ後続２］, registered in Japan by 陽進堂ホールディングス, on the national reimbursement list.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ウステキヌマブ（遺伝子組換え）［ウステキヌマブ後続２］
- Manufacturer
- 陽進堂ホールディングス
- Country
- Japan (JP)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
ウステキヌマブ（遺伝子組換え）［ウステキヌマブ後続２］ in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesIMULDOSAAccord BioPharma Inc.
- FinlandABSIMKYAccord Healthcare S.L.U.
- BelgiumAbsimky 130 mgAccord Healthcare
- CzechiaFYMSKINAFormycon AG, Martinsried/Planegg
- SwedenFymskina 130 mg Koncentrat till infusionsvätska, lösningFormycon AG
- PolandAbsimkyAccord Healthcare S.L.U.
- IcelandFymskinaFormycon AG
- NetherlandsFymskina 130 mg concentraat voor oplossing voor infusieFormycon AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Imuldosa, Uzpruvo
- Iceland · Fymskina, Imuldosa
- Liechtenstein · Fymskina, Imuldosa
- Norway · Fymskina, Imuldosa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba5ddb6d-d3e0-436d-add1-a8988340e81c GET /v1/drugs/ba5ddb6d-d3e0-436d-add1-a8988340e81c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "４５ｍｇ０．５ｍＬ１筒",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "3999474G1023",
"category": "注射薬",
"price_yen": 136554,
"generic_name": "ウステキヌマブ（遺伝子組換え）［ウステキヌマブ後続２］",
"product_name_jp": null,
"therapeutic_class": "3999",
"transitional_expiry": null
}See everything about ウステキヌマブ（遺伝子組換え）［ウステキヌマブ後続２］.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.